QUASAR Therapeutics
Our teams
Transforming therapies for complement-mediated diseases
QUASAR Therapeutics develops novel regulators of the complement system to transform the treatment of life-threatening diseases. Current inhibitors in the clinic are insufficient and patients still suffer from their symptoms despite complement inhibition. We solve this problem with our novel regulators based on human complement proteins. This has been proven by a compelling set of in vitro, ex vivo, and in vivo data for our lead candidate.
Incorporation planned for 2026.
Vision of QUASAR Therapeutics:
"Since our participation in the Biotech Bootcamp, we have been part of BioM's impressive ecosystem and have been supported ever since. Today, we are very happy and grateful to have joined the MAxL Incubator, because this is the right place to realize our vision."
The team of QUASAR Therapeutics:
- Matteo Mohr, Co-Founder and CEO - LinkedIn profile
- Dr. Arthur Dopler, Co-Founder and CSO - LinkedIn profile
- Dr. Monika Hunjadi
- Prof. Dr. Christoph Schmidt
- Prof. Dr. Markus Huber-Lang (not pictured)